CNTB NASDAQ
Connect Biopharma Holdings Limited
1W: -14.2%
1M: -66.4%
3M: -60.7%
YTD: -63.2%
1Y: -38.2%
3Y: +27.0%
5Y: -95.7%
$0.93
-0.05 (-5.38%)
Weekly Expected Move ±21.6%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (29)
3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
Connect Biopharma drops as asthma candidate fails in mid-stage trial
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Receives $7.43 Consensus Target Price from Brokerages
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
HC Wainwright Issues Pessimistic Forecast for CNTB Earnings
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Brokerages Set Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Price Target at $7.29
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
Northland Securities Weighs in on CNTB Q1 Earnings
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
Equities Analysts Offer Predictions for CNTB Q1 Earnings
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of “Moderate Buy” by Analysts
Connect Biopharma (NASDAQ:CNTB) Director James Huang Acquires 1,160,000 Shares
12 Health Care Stocks Moving In Wednesday's After-Market Session
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
Connect Biopharma Announces $20.2 Million Private Placement Financing
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Most and least shorted healthcare stocks with up to $2B market cap in February
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of “Moderate Buy” by Analysts
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Receives Average Rating of “Moderate Buy” from Brokerages
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026